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to 6 (18%), while in the calcium group, the number of patientsA multicenter study on the affects of lanthanum carbonate
with these types of ROD increased from 13 (43%) to 16 (53%).(Fosrenol) and calcium carbonate on renal bone disease in
Conclusion. LC is a poorly absorbed, well-tolerated, anddialysis patients.
efficient phosphate binder. LC-treated dialysis patients showBackground. Lanthanum carbonate (LC) (Fosrenol) is a
almost no evolution toward low bone turnover over one yearnovel new treatment for hyperphosphatemia. In this phase III,
(unlike CC-treated patients), nor do they experience any alumi-open-label study, we compared the effects of LC and calcium
num-like effects on bone.carbonate (CC) on the evolution of renal osteodystrophy
(ROD) in dialysis patients.
Methods. Ninety-eight patients were randomized to LC
(N 49) or CC (N 49). Bone biopsies were taken at baseline
Hyperphosphatemia continues to be a challenge forand after one year of treatment. Acceptable paired biopsies
the clinical nephrologist, as it may lead to extraosseouswere available for static and dynamic histomorphometry stud-
calcification of both vascular and nonvascular tissues,ies in 33 LC and 30 CC patients. Blood samples were taken
at regular intervals for biochemical analysis and adverse events secondary hyperparathyroidism, and osteitis fibrosa, par-
were monitored. ticular types of renal osteodystrophy (ROD) responsi-
Results. LC was well tolerated and serum phosphate levels ble for significant morbidity [1, 2]. To prevent hyper-were well controlled in both treatment groups. The incidence
phosphatemia, most patients with end-stage renal failureof hypercalcemia was lower in the LC group (6% vs. 49% for
require an exogenous phosphate binder.CC). At baseline, subtypes of ROD were similarly distributed
in both groups, with mixed ROD being most common. At one- Aluminium-containing phosphate binders have been
year follow-up in the LC group, 5 of 7 patients with baseline widely used in the past. The systemic absorption of alu-
low bone turnover (either adynamic bone or osteomalacia), minium hydroxide over time, however, can lead to theand 4 of 5 patients with baseline hyperparathyroidism, had
development of the so-called aluminium-related boneevolved toward a normalization of their bone turnover. Only
diseases (either osteomalacia or adynamic bone), de-one lanthanum-treated patient evolved toward adynamic bone
compared with 6 patients in the CC group. In the LC group, mentia, and more subtle disorders at the level of the
the number of patients having either adynamic bone, osteoma- parathyroid gland, hematopoiesis, and myopathy [3, 4].
lacia, or hyperpara decreased overall from 12 (36%) at baseline The use of calcium salts for phosphate binding is com-
plicated by the development of hypercalcemia and an
increased risk of metastatic calcifications in a substantialKey words: phosphate binder, osteodystrophy, bone histomorpho-
metry, chronic renal failure, open-label study. fraction of patients, particularly those taking vitamin D
analogs and those with adynamic bone disease [5–7]. 2003 by the International Society of Nephrology
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Alternative phosphate binders have been developed modialysis or CAPD) within the 12 weeks prior to study
in recent years with the aim of avoiding side effects entry, or had been diagnosed with chronic renal failure
during phosphate control. Polyallylamine-hydrochloride and were scheduled to begin dialysis prior to randomiza-
(sevelamer, RenaGel) is a nonabsorbed cationic poly- tion. No preset limit was applied to serum PTH on entry
mer that binds phosphate anions through ion exchange to the study and there was no restriction of concomitant
and hydrogen binding. This class of compounds was orig- vitamin D therapy. Patients with significant hypocal-
inally developed to lower plasma lipids; this effect is still cemia or concurrent illness were excluded.
seen with sevelamer [8]. Compared to calcium-based A total of 98 patients (‘intent to treat’ patients) were
phosphate binders, evidence has shown that with seve- randomized to the study medication and received at least
lamer, fewer coronary and aortic calcifications are seen one dose of lanthanum carbonate (N  49) or calcium
[9]. However, the efficacy of this polymer in lowering carbonate (N  49). In this group all aspects of efficacy,
phosphate levels is still a matter of debate, as the target safety, and tolerability were monitored. Safety was as-
serum phosphate level of 5.5 mg/dL cannot be reached in sessed at each study visit by recording adverse events
the majority of patients, especially when the compound is and vital signs. Full blood biochemical and hematologic
used as monotherapy [10]. Moreover, as a lipid-binding parameters were monitored and the plasma levels of
compound, sevelamer has the ability to sequester fat-
lanthanum were measured at visits throughout the study.soluble vitamins and nutrient compounds [11]. Although
Patients were recruited from 18 centers in 12 countries.no problems in this respect have emerged so far, more
The mean  SD age was 55  14.3 years; 59 (60%)information on long-term safety is required.
patients were males. There was no relevant differenceBecause the solubility product of trivalent iron and
between treatment groups with respect to underlyingphosphate is extremely low, polynuclear iron prepara-
nephrologic diagnosis: diabetes (26%); glomerulone-tions constitute another group of alternative phosphate
phritis (9%); other known disease (12%); unknownbinders. The use of trivalent iron has recently generated
cause (14%); cystic kidney disease (14%); hypertensionsubstantial interest; it is effective and well tolerated, but
(14%); and urologic disease (10%).is still in the early stages of clinical development [12].
A total of 68 patients (N  34 in each group) com-A third alternative is lanthanum carbonate. Lantha-
pleted the study (i.e., underwent a bone biopsy at base-num, discovered in 1839 by Mosander, is a rare earth
line and follow-up. Patients discontinued the study be-element (molecular weight: 139 kD). As this trivalent
cause of the investigator’s decision (N  1); protocolhard acid cation has a high affinity for phosphate (phos-
violation (N 1); kidney transplantation (N 10); deathphate binding capacity in vitro 97%), is minimally ab-
sorbed gastrointestinally, is not excreted by the kidneys, (N  11); serious adverse events (N  2); and others
and is well tolerated, the investigation of lanthanum as (N  5). Of the patients randomized, 63 pairs of bone
a phosphate binder is warranted [13]. The excretion of biopsies were suitable for histomorphometric measure-
absorbed lanthanum by the biliary system contrasts with ments, 33 of which belonged to the lanthanum group
aluminium, which is excreted almost entirely (95%) and 30 to the calcium group.
in the urine and, consequently, is associated with an Written informed consent was obtained from all pa-
increased risk of toxicity in patients with renal disease tients and the study was conducted in compliance with
[14]. Plasma lanthanum concentrations have rarely ex- the declaration of Helsinki and approved by Local Ethi-
ceeded one part per billion. There has been no evidence cal Committees at each of the participating centers.
of lanthanum toxicity in any of the clinical studies hith-
erto performed. Study set up
In light of the past tragic experience with aluminium in The study was conducted over a one-year period. Fol-
dialysis patients, information on the effects of lanthanum lowing screening, all phosphate binders were stopped
carbonate on bone is necessary. The present bone and double tetracycline labeling administered, with an
biopsy-based study aimed to: investigate the effect of interval of 8 to 12 days. A baseline bone biopsy was
phosphate management by the administration of lantha-
taken 2 to 6 days following the second label. Patientsnum carbonate compared with calcium carbonate on re-
were then randomized in a 1:1 ratio to receive lanthanumnal bone disease; check the lanthanum accumulation in
or calcium carbonate. All patients were titrated to abone; and evaluate long-term safety and tolerability of
lanthanum dose (up to 3750 mg/day) or calcium (up tolanthanum in dialysis patients after one year of treat-
9000 mg/day) that achieved optimal reduction of serumment.
phosphate levels, and were maintained at this dose, or
titrated further when necessary. The second biopsy was
METHODS obtained following double tetracycline labeling and one
Patients year of treatment, or at time of discontinuation if 6
months treatment received. A follow-up period was in-Key inclusion criteria were male or female patients
aged 18 years who had started dialysis treatment (he- cluded, during which patients were examined and all
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adverse events reviewed 28 days after discontinuation There was, however, a higher incidence of hypercalcemia
of the study medication (or early withdrawal from the (serum calcium above upper limit of normal) (i.e.,2.65
study). mmol/L or 10.6 mg/dL) in the patients treated with
calcium carbonate (49%) compared to those receiving
Laboratory methods lanthanum carbonate during the study period (6%).
Blood and bone biochemistry. Blood samples were There were no significant differences in hematologic
taken at study visits throughout the study period for the or biochemical safety parameters over time. A more
determination of a series of routine biochemistry and detailed description of clinical safety results will be pre-
hematology screening tests. In addition, a panel of serum sented elsewhere.
parameters relevant to bone [i.e., phosphorous, calcium, There were no significant differences in the concentra-
bone specific and total alkaline phosphatase, iPTH, 25- tion of the various biochemical bone-related parameters
(OH)-, vitamin D, and 1,25-(OH)2 vitamin D] were mea- between the two groups; these parameters also did not
sured using the appropriate kits and methodologies. significantly change during the study period (Fig. 1).
Lanthanum was measured in plasma and bone by Both treatment groups showed well controlled phospho-
means of inductively-coupled plasma mass spectrometry rus levels throughout the trial, using doses up to 3750
(ICP-MS) using methodologies developed and optimized mg/day for lanthanum (median dose 1250 mg/day), and
at the Centre for Analytical Sciences (CAS) at the Uni- 9000 mg/day (median dose 2000 mg/day) for calcium
versity of Sheffield, United Kingdom. carbonate. With respect to vitamin D usage, no differ-
Bone histomorphometry. In each patient, a single ences were noticed between treatment groups (lantha-
transiliac bone biopsy ( 1 cm length; 5 or 7 mm diame- num: 63% vs. calcium: 53%).
ter) was taken after double tetracycline labeling. The Patients of the lanthanum group had plasma lantha-
biopsy was divided into two parts. One part (mainly num levels that were slightly increased for all doses ad-
cortical bone) was used to measure the bulk lanthanum ministered, compared with baseline levels of patients
content. The remaining part was fixed in absolute ethanol receiving 1500 to 2250 mg lanthanum per day, with mean
and then embedded in a methylmethacrylate-based resin plasma lanthanum levels ranging from 0.51 to 1.08 g/L.
for histology and histomorphometric analysis. Unde- Lanthanum levels did not depend on the dose adminis-
calcified 7-m thick sections were stained with Toluidine tered and reached a plateau after 12 weeks of treatment.
blue [15]. Seven-m sections were mounted unstained The patients treated with lanthanum carbonate for up
in immersion oil for visualization of tetracycline labels. to one year had a median bone concentration of 1.8 g/g,
Criteria for classification of the various types of ROD the highest value in any patient being 5.5 g/g. In the cal-
were: cium carbonate group, bone lanthanum levels at the end
of the study also showed a slight increase, with the high-
Adynamic bone disease: Bone formation rate (BFR) est value in any patient being 1.0 g/g.
5% of age- and sex-corrected mean and osteoclast The histomorphometric data are shown in Figure 2.
surface (OcS) 20% of age- and sex-corrected mean. Five out of 7 patients (71%) of the lanthanum group
Hyperparathyroidism: BFR 2x age- and sex-corrected with either adynamic bone or osteomalacia at baseline
mean and OcS 100x age- and sex-corrected mean. (Fig. 2, upper panels), and 4 out of 5 patients (80%) with
Normal: BFR and OcS within 2SD of the age- and sex-
baseline hyperparathyroidism (Fig. 2, lower panels)
corrected mean.
evolved toward a normalization of their bone turnover
Osteomalacia: Mineralization lag time (MLT)100 days
as compared to only 3 out of 7 (42%) and 3 out of 6
and osteoid volume5x age- and sex-corrected mean.
(50%) of the calcium group.
Mixed ROD: All bone biopsies that do not fulfill the
Twenty-six (26) patients (79%) of the lanthanumcriteria listed above.
group and 23 (77%) of the calcium group had a normal
or increased bone turnover (hyperpara, mixed, normal)
RESULTS at baseline. Both groups showed markedly different re-
sponses. While 6 out of 23 patients (26%) of the calciumLanthanum carbonate taken with meals was well toler-
group developed adynamic bone disease, this was seenated throughout the study period. The type and incidence
in only 1 out of 26 patients (4%) of the lanthanum groupof adverse events were well balanced between the two
(Fig. 2, upper panels). This particular lanthanum-treatedtreatment groups, with 96% of patients in both groups
patient had been taking oral calcitriol throughout thereporting at least one treatment-emergent adverse effect.
study at varying doses (0.5 to 1.5g TDS), despite havingGastrointestinal effects were the most common events
a PTH (baseline, 4.56 pmol/L to follow-up, 5.53 pmol/L)and were typically mild (lanthanum: 53% vs. calcium:
below the optimum level for an end-stage renal failure49%). Withdrawal rates due to adverse events were com-
parable between lanthanum (24%) and calcium (22%). patient, and having a good control of serum phosphate
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The distribution of the various types of ROD assessed
at baseline using the proposed criteria for classification
was similar in both treatment groups (Fig. 2, lower
panels).
Overall, in the lanthanum group the total number of
patients having either adynamic bone, osteomalacia, or
hyperpara decreased from 12 (36%) at baseline, to 6
(18%) at one-year follow-up, while in the calcium group,
the number of patients with these types of ROD in-
creased from 13 (43%) to 16 (53%) (Fig. 2, lower panels).
DISCUSSION
Treatment of uremic hyperphosphatemia remains a
major challenge to the nephrologist because phosphate
retention is associated with a variety of clinical problems,
including secondary hyperparathyroidism and soft tissue
mineralization.
Until now, aluminium-containing and calcium-based
phosphate binders have been most frequently used in
the treatment of hyperphosphatemia. Although highly
efficacious, the chronic therapeutic use of these com-
pounds goes along with serious side effects [3–5, 16].
Lanthanum carbonate has recently been proposed as a
nontoxic and efficacious alternative.
In this phase III, open-label study, we compared the
effects of a one-year treatment with either lanthanum
carbonate or calcium carbonate on the evolution of renal
bone disease in dialysis patients.
The serious adverse events for both treatment groups
observed during the study period were balanced and
were typical for a population with chronic renal failure
receiving hemodialysis or peritoneal dialysis. Thus, data
of the present study confirms the safe profile of lantha-
num previously observed in phase II studies [17]. The
incidence and types of adverse effects were similar in
the two treatment groups. An exception to this was hy-
percalcemia, which was appreciably lower in the lantha-
num-treated group compared to the calcium carbonate
group (6% and 49%, respectively).
Despite the additional calcium intake in the calcium
carbonate group, mean serum calcium levels did not
differ significantly between the groups, which must be
ascribed to careful monitoring of calcemia throughout
the study and immediate adjustment of the dialysate
Fig. 1. Comparison and temporal evolution of some relevant bone- calcium concentration or vitamin D intake. Nevertheless,
related parameters in both study groups. the number of hypercalcemic episodes was substantially
greater in the calcium carbonate group. This reduced
propensity for hypercalcemic episodes on lanthanum car-(mean, 1.53 mmol/L) and serum calcium (mean, 2.38
bonate must be considered a major benefit.mmol/L) throughout the study period.
The serum phosphate levels were well controlled inFive patients (1 with osteomalacia and 4 with mixed
both treatment groups throughout the study. There wasbone disease at baseline) of the calcium group (17%)
little change in iPTH or bone alkaline phosphatase con-developed hyperpara compared to only 2 patients (mixed
centration in either treatment group during the studybone disease at baseline) of the lanthanum group (7.5%)
(Fig. 2, lower panels). period.
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Fig. 2. Patients with either low bone turn-
over at baseline and those evolving toward
low bone turnover at follow-up in both study
groups are shown in the upper panels. Lower
panels show temporal evolution of renal bone
disease of all patients after one year of treat-
ment with either lanthanum or calcium car-
bonate. Values between brackets indicate the
prevalence of the various types of ROD.
Weighing any toxic effects of lanthanum against those in bone and plasma after a one-year treatment, being
10- to 50-fold lower than those expected for aluminiumexperienced in the past with aluminium, the highly lim-
ited gastrointestinal absorption of lanthanum (0.00003% [4]. Data furthermore has indicated that plasma lantha-
num reached steady state early (i.e., after 12 weeks) infor lanthanum vs. 0.02% for aluminum), and the non-
renal routes of excretion for the absorbed fraction of the the study.
To the best of our knowledge, this is the first bonedose of lanthanum should be considered [18]. This is re-
flected by the very low concentrations of lanthanum found biopsy-based multicenter study to investigate and com-
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